Vanda Pharmaceuticals (NASDAQ:VNDA) Stock: Insider Charles Cliff Duncan Buys 3,447 Shares

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Director Charles Duncan acquired 3,447 shares of the company’s stock in a transaction dated Wednesday, November 4th. The shares were purchased at an average cost of $3.82 per share, with a total value of $13,167.54. Following the acquisition, the director owned 102,898 shares of the company’s stock, valued at approximately $393,070.36. This represents a 3.47% increase in their position. The acquisition was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Charles Cliff Duncan also recently made the following trade(s):

• On Thursday, November 5th, Charles Duncan bought 5,803 shares of Vanda Pharmaceuticals stock. The stock was acquired at an average cost of $3.80 per share, for a total transaction of $22,051.40.
• On Tuesday, November 3rd, Charles Duncan acquired 750 shares of Vanda Pharmaceuticals stock. The shares were bought at an average cost of $3.80 per share, for a total transaction of $2,850.00.

Vanda Pharmaceuticals Price Performance

Shares of NASDAQ:VNDA opened at $3.82 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.53 and a current ratio of 1.54. Vanda Pharmaceuticals Inc. has a 1-year low of $3.57 and a 1-year high of $9.94. The business has a fifty day moving average price of $4.63 and a 200-day moving average price of $6.12.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, October 28th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.68) by $0.31. Vanda Pharmaceuticals had a negative return on equity of 62.70% and a negative net margin of 119.87%. The business had revenue of $69.81 million during the quarter, compared to analysts’ expectations of $69.20 million. As a group, analysts anticipate that Vanda Pharmaceuticals Inc. will post -2.53 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have recently commented on VNDA shares. Oppenheimer initiated coverage on shares of Vanda Pharmaceuticals in a research report on Wednesday, September 23rd. They issued an “outperform” rating and a $10.00 price objective for the company. B. Riley Financial reissued a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a research report on Monday, August 10th. Wall Street Zen upgraded Vanda Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, October 31st. Zacks Research raised Vanda Pharmaceuticals from a “strong sell” rating to a “hold” rating in a report on Wednesday. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a research note on Thursday, October 15th. Six analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $13.50.

Hedge Funds Weigh In On Vanda Pharmaceuticals

A number of large investors have recently made changes to their positions in VNDA. BlackRock Inc. purchased a new stake in Vanda Pharmaceuticals during the 2nd quarter worth approximately $46,841,000. Monaco Asset Management SAM acquired a new stake in shares of Vanda Pharmaceuticals during the 2nd quarter valued at $1,354,000. State Street Corp increased its holdings in Vanda Pharmaceuticals by 16.6% in the 2nd quarter. State Street Corp now owns 3,516,405 shares of the biopharmaceutical company’s stock worth $21,520,000 after acquiring an additional 500,843 shares during the last quarter. Connor Clark & Lunn Investment Management Ltd. purchased a new position in Vanda Pharmaceuticals during the 2nd quarter valued at $1,317,000. Finally, Arrowstreet Capital Limited Partnership bought a new stake in shares of Vanda Pharmaceuticals during the 1st quarter valued at $1,668,000. Hedge funds and other institutional investors own 88.14% of the company’s stock.

About Vanda Pharmaceuticals

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.